Table 1.
Characteristics of 61 patients undergoing SRT and comparison of SRT success group and SRT failure group
| Variables | Total (n = 61) | SRT success (n = 30) | SRT failure (n = 31 ) | SRT Success vsSRT failure Pvalue |
|---|---|---|---|---|
| Age at SRT (median, range) | 69 (57–78) | 70 (58–77) | 69 (57–78) | 0.88 † |
| Initial PSA (mean, SD) | 12.5 ± 14.5 | 14.3 ± 19.7 | 10.7 ± 6.4 | 0.96 † |
| Clinical T stage | 0.47 ‡ | |||
| T1c | 24 | 13 | 11 | |
| T2 | 29 | 12 | 17 | |
| T3 | 8 | 5 | 3 | |
| NCCN risk classification | 0.086 ‡ | |||
| Low | 10 | 8 | 2 | |
| Intermidiate | 28 | 11 | 17 | |
| High / Very high | 23 | 11 | 12 | |
| Prostatectomy Gleason score | 0.17 ‡ | |||
| 6 | 6 | 5 | 1 | |
| 7 | 35 | 18 | 17 | |
| 8 | 8 | 2 | 6 | |
| 9 | 12 | 5 | 7 | |
| Prostatectomy pathological T stage | 0.84 ‡ | |||
| T2a | 10 | 6 | 4 | |
| T2b | 10 | 4 | 6 | |
| T2c | 14 | 7 | 7 | |
| T3a / b | 27 | 13 | 14 | |
| Prostatectomy lymphatic invasion (ly) | 0.23 ‡ | |||
| Negative | 46 | 25 | 21 | |
| Positive | 15 | 5 | 10 | |
| Prostatectomy perineural invasion (pn) | 0.79 ‡ | |||
| Negative | 23 | 12 | 11 | |
| Positive | 38 | 18 | 20 | |
| Prostatectomy Seminal vesicle involvement | 0.97 ‡ | |||
| Negative | 57 | 28 | 29 | |
| Positive | 4 | 2 | 2 | |
| Surgical margins | 0.075 ‡ | |||
| Negative | 30 | 11 | 19 | |
| Positive | 31 | 19 | 12 | |
| Time to PSA nadir after prostatectomy (months) | 2.4 (0.8 - 17.9) | 2.3 (0.8 - 15.8) | 2.5 (0.9 - 17.9) | 0.22 † |
| PSA nadir after prostatectomy (ng/mL) | 0.140 ± 0.238 | 0.116 ± 0.214 | 0.163 ± 0.262 | 0.35 † |
| Pre-SRT PSA (ng/mL) | 0.56 ± 0.49 | 0.37 ± 0.25 | 0.75 ± 0.59 | 0.021 † |
| PSAV after PSA recurrence (ng/mL/year) | 0.19 ± 1.40 | 0.38 ± 0.40 | 1.43 ± 1.79 | < 0.0001 † |
| PSADT after PSA recurrence (months) | 7.44 ± 7.27 | 9.89 ± 9.02 | 5.07 ± 3.94 | 0.0049 † |
| Follow up period after SRT (months) | 29.6 (12.0 - 70.0) | 24.6 (12.0 - 70.0) | 31.2 (12.0 - 64.6) | 0.83 † |
SRT = salvage radiotherapy; PSA = prostate-specific antigen; SD = standard deviation; NCCN = The National Comprehensive Cancer Network; PSAV = PSA velocity; PSADT = PSA doubling time; † Man-Whitney U test; ‡ Chi-square test or Fisher’s exact test.